As oncology drug development becomes more biomarker-driven, the industry is rethinking what meaningful early insight looks like and how it can shape better decisions across the life cycle of a program. In this episode of The Top Line, leaders from Myriad Genetics examine why tumor-informed molecular residual disease, or MRD, testing is moving beyond a promising innovation and becoming a strategic advantage in modern drug development.
The conversation explores how highly sensitive, tumor-informed MRD assays can potentially reveal response depth, durability and trajectory far earlier than traditional approaches. That shift is not only expanding what teams may be able to measure but also may be changing how they think about trial design, patient selection and regulatory planning when programs must move with speed but still stand up to scrutiny.
Speakers also make the case that diagnostics should not be treated as a downstream consideration. When MRD strategy is introduced earlier, biopharma teams may be better positioned to define more meaningful thresholds, potentially reduce uncertainty sooner and build programs that are more adaptable as the evidence and regulatory landscape continue to evolve.